Deciphera Pharmaceuticals (NASDAQ:DCPH) reported Q2 EPS of ($0.60), $0.06 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $32.5 million versus the consensus estimate of $30.58 million.
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported Q2 EPS of ($0.60), $0.06 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $32.5 million versus the consensus estimate of $30.58 million.